OCT in Rare Chorioretinal Diseases

Status Recruiting

Clinical Trial Summary

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.

Clinical Trial Description

Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time by measuring the intensity of reflected light. Tomographic images are generated by scanning the optical probe beam across the tissue structure of interest. OCT has become one of the most widely used imaging technologies by ophthalmologists. Its advantages include being a non-contact imaging modality, having micron-level resolution, producing a digital image that can be viewed electronically, and providing a reproducible quantitative measurement. New functional OCT including Doppler OCT and OCT angiography may allow an assessment of retinal blood flow and do away with the need for the more invasive fluorescein angiography (FA) test. Thus, if the diagnostic data provided by functional OCT are at least equivalent or superior to those achieved by FA, patients and healthcare providers could realize a substantial benefit in utilizing this technology in the evaluation of retinal vascular disease. Even in the scenario in which an FA is not usually clinically indicated, OCT angiography may provide information over that of standard OCT and clinical examination and history, that might help clinicians better understand the etiology of the disease, and may even help inform treatment response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02141308
Study type	Observational
Source	Oregon Health and Science University
Contact	Kevin Lathrop
Phone	503-494-8024
Email	lathropk@ohsu.edu
Status	Recruiting
Phase
Start date	May 2014
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03497000` - Effects of OCTA-guided PDT in Acute CSC	N/A
Recruiting	`NCT03692169` - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting	`NCT02215330` - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy	Phase 2/Phase 3
Completed	`NCT01971190` - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy	Phase 2
Completed	`NCT01990677` - Eplerenone for the Treatment of Central Serous Chorioretinopathy	N/A
Active, not recruiting	`NCT01710332` - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy	Phase 2
Active, not recruiting	`NCT00403884` - Selective RPE Laser Treatment (SRT) for Various Macular Diseases	N/A
Recruiting	`NCT05570591` - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy	N/A
Recruiting	`NCT05589974` - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed	`NCT05104138` - Eplerenone Versus PDT: Comparative Study by OCTA
Completed	`NCT01880788` - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD	N/A
Terminated	`NCT01982383` - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy	N/A
Completed	`NCT01327170` - Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy	N/A
Completed	`NCT01019668` - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy	N/A
Recruiting	`NCT06346405` - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Completed	`NCT01822561` - Eplerenone for Central Serous Chorioretinopathy	Phase 2
Completed	`NCT00802906` - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)	N/A
Withdrawn	`NCT05679180` - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE	N/A
Completed	`NCT05686421` - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations	N/A
Completed	`NCT03758963` - Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.